Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
grade D 10.06 1.62% 0.16
STRO closed up 1.62 percent on Tuesday, April 23, 2019, on 1.52 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical STRO trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 1.62%
Stochastic Reached Oversold Weakness 1.62%
Multiple of Ten Bearish Other 1.62%

Older signals for STRO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Medicine Cancer Clinical Medicine Immunology California Antibodies Drug Discovery Cancer Treatments Antineoplastic Drugs Multiple Myeloma Sutro Biopharma Autoimmune Disorders Non Hodgkin Lymphoma Adc Immunogen South San Francisco Therapeutics For Cancer Milatuzumab
Is STRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.9
52 Week Low 8.5
Average Volume 25,774
200-Day Moving Average 0.0
50-Day Moving Average 10.5572
20-Day Moving Average 11.099
10-Day Moving Average 10.937
Average True Range 0.816
ADX 17.99
+DI 16.2738
-DI 26.0479
Chandelier Exit (Long, 3 ATRs ) 10.022
Chandelier Exit (Short, 3 ATRs ) 11.727999999999999
Upper Bollinger Band 12.2162
Lower Bollinger Band 9.9818
Percent B (%b) 0.03
BandWidth 20.131543
MACD Line -0.0688
MACD Signal Line 0.1335
MACD Histogram -0.2023
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.68
Resistance 3 (R3) 11.70 11.18 11.41
Resistance 2 (R2) 11.18 10.77 11.17 11.32
Resistance 1 (R1) 10.62 10.51 10.90 10.60 11.23
Pivot Point 10.10 10.10 10.24 10.09 10.10
Support 1 (S1) 9.54 9.69 9.82 9.52 8.89
Support 2 (S2) 9.02 9.43 9.01 8.80
Support 3 (S3) 8.46 9.02 8.71
Support 4 (S4) 8.44